# Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure

> **NCT04322773** · PHASE2 · TERMINATED · sponsor: **Marius Henriksen** · enrollment: 20 (actual)

## Conditions studied

- Corona Virus Disease

## Interventions

- **DRUG:** RoActemra iv
- **DRUG:** RoActemra sc
- **DRUG:** Kevzara sc
- **OTHER:** Standard medical care

## Key facts

- **NCT ID:** NCT04322773
- **Lead sponsor:** Marius Henriksen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-05
- **Primary completion:** 2020-10-08
- **Final completion:** 2020-10-08
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The study has been terminated due to changed clinical conditions and too few patients available
- **Last updated:** 2020-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322773, "Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04322773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*